Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 757

1.

A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.

Ueda Y, Matsubara N, Takizawa I, Nishiyama T, Tabata K, Satoh T, Kamiya N, Suzuki H, Kawahara T, Uemura H.

Jpn J Clin Oncol. 2015 Aug;45(8):774-9. doi: 10.1093/jjco/hyv070.

PMID:
25981621
2.

Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.

Azad AA, Eigl BJ, Murray RN, Kollmannsberger C, Chi KN.

Eur Urol. 2015 Jan;67(1):23-9. doi: 10.1016/j.eururo.2014.06.045.

PMID:
25018038
3.

Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.

Maughan BL, Xhou XC, Suzman DL, Nadal R, Bassi S, Schweizer MT, Antonarakis ES.

Prostate. 2015 Nov;75(15):1814-20. doi: 10.1002/pros.23064.

PMID:
26306637
4.

A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer.

Azad AA, Leibowitz-Amit R, Eigl BJ, Lester R, Wells JC, Murray RN, Kollmannsberger C, Heng DY, Joshua AM, Chi KN.

Prostate. 2014 Nov;74(15):1544-50. doi: 10.1002/pros.22872.

PMID:
25175831
5.

Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis.

Brasso K, Thomsen FB, Schrader AJ, Schmid SC, Lorente D, Retz M, Merseburger AS, von Klot CA, Boegemann M, de Bono J.

Eur Urol. 2015 Aug;68(2):317-24. doi: 10.1016/j.eururo.2014.07.028.

PMID:
25108579
6.

Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort.

Höfner T, Vallet S, Hadaschik BA, Pahernik S, Duensing S, Hohenfellner M, Jäger D, Grüllich C.

World J Urol. 2015 Jun;33(6):833-9. doi: 10.1007/s00345-014-1375-5.

PMID:
25113804
7.

The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer.

Schweizer MT, Zhou XC, Wang H, Bassi S, Carducci MA, Eisenberger MA, Antonarakis ES.

Eur Urol. 2014 Oct;66(4):646-52. doi: 10.1016/j.eururo.2014.01.018.

8.

Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.

Pezaro CJ, Omlin AG, Altavilla A, Lorente D, Ferraldeschi R, Bianchini D, Dearnaley D, Parker C, de Bono JS, Attard G.

Eur Urol. 2014 Sep;66(3):459-65. doi: 10.1016/j.eururo.2013.11.044.

PMID:
24411987
9.

CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.

Wissing MD, Coenen JL, van den Berg P, Westgeest HM, van den Eertwegh AJ, van Oort IM, Bos MM, Bergman AM, Hamberg P, Ten Tije AJ, Los M, Lolkema MP, de Wit R, Gelderblom H.

Int J Cancer. 2015 Mar 15;136(6):E760-72. doi: 10.1002/ijc.29231.

10.

A phase 2 study of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer who had received docetaxel-based chemotherapy.

Satoh T, Uemura H, Tanabe K, Nishiyama T, Terai A, Yokomizo A, Nakatani T, Imanaka K, Ozono S, Akaza H.

Jpn J Clin Oncol. 2014 Dec;44(12):1206-15. doi: 10.1093/jjco/hyu148.

11.

Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status.

Azad AA, Eigl BJ, Leibowitz-Amit R, Lester R, Kollmannsberger C, Murray N, Clayton R, Heng DY, Joshua AM, Chi KN.

Eur Urol. 2015 Mar;67(3):441-7. doi: 10.1016/j.eururo.2014.01.030.

PMID:
24508071
12.

A phase 2 trial of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer and without prior chemotherapy (JPN-201 study).

Matsubara N, Uemura H, Satoh T, Suzuki H, Nishiyama T, Uemura H, Hashine K, Imanaka K, Ozono S, Akaza H.

Jpn J Clin Oncol. 2014 Dec;44(12):1216-26. doi: 10.1093/jjco/hyu149.

13.

Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.

Zhang T, Dhawan MS, Healy P, George DJ, Harrison MR, Oldan J, Chin B, Armstrong AJ.

Clin Genitourin Cancer. 2015 Aug;13(4):392-9. doi: 10.1016/j.clgc.2015.01.004.

PMID:
25708161
14.

Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.

Pond GR, Armstrong AJ, Galsky MD, Wood BA, Leopold L, Sonpavde G.

Urol Oncol. 2013 Nov;31(8):1457-63. doi: 10.1016/j.urolonc.2012.02.008.

PMID:
22552048
15.

Clinical effect of abiraterone acetate in Korean patients with metastatic castration-resistant prostate cancer according to duration of androgen deprivation therapy.

Kim KB, Jo JK, Ahn S, Lee S, Jeong SJ, Hong SK, Byun SS, Lee SE.

Korean J Urol. 2015 Aug;56(8):580-6. doi: 10.4111/kju.2015.56.8.580.

16.

Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: a phase II bridging study in Korean and Taiwanese patients.

Kwak C, Wu TT, Lee HM, Wu HC, Hong SJ, Ou YC, Byun SS, Rhim HY, Kheoh T, Wan Y, Yeh H, Yu MK, Kim CS.

Int J Urol. 2014 Dec;21(12):1239-44. doi: 10.1111/iju.12589.

17.

Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.

Sternberg CN, Castellano D, Daugaard G, Géczi L, Hotte SJ, Mainwaring PN, Saad F, Souza C, Tay MH, Garrido JM, Galli L, Londhe A, De Porre P, Goon B, Lee E, McGowan T, Naini V, Todd MB, Molina A, George DJ; Abiraterone Global EAP Investigators..

Lancet Oncol. 2014 Oct;15(11):1263-8. doi: 10.1016/S1470-2045(14)70417-6. Erratum in: Lancet Oncol. 2014 Nov;15(12):e528.

PMID:
25242048
18.

Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy.

Mulders PF, Molina A, Marberger M, Saad F, Higano CS, Chi KN, Li J, Kheoh T, Haqq CM, Fizazi K.

Eur Urol. 2014 May;65(5):875-83. doi: 10.1016/j.eururo.2013.09.005.

PMID:
24099659
19.

Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment.

Aggarwal R, Harris A, Formaker C, Small EJ, Molina A, Griffin TW, Ryan CJ.

Clin Genitourin Cancer. 2014 Oct;12(5):e167-72. doi: 10.1016/j.clgc.2014.03.010.

PMID:
24787968
20.

Third-line Enzalutamide Following Docetaxel and Abiraterone in Metastatic Castrate-resistant Prostate Cancer.

Davies RS, Smith C, Lester JF.

Anticancer Res. 2016 Apr;36(4):1799-803.

PMID:
27069162
Items per page

Supplemental Content

Support Center